PCM Encore LLC Acquires New Position in Gilead Sciences, Inc. $GILD

PCM Encore LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 7,399 shares of the biopharmaceutical company’s stock, valued at approximately $935,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in Gilead Sciences in the 2nd quarter valued at approximately $15,393,785,000. Norges Bank purchased a new stake in shares of Gilead Sciences during the fourth quarter worth $2,617,152,000. Deutsche Bank AG purchased a new stake in shares of Gilead Sciences during the second quarter worth $918,387,000. Boston Partners acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Gilead Sciences in the second quarter valued at $398,905,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s collaboration with Nucleai highlights a potential strategic shift toward data-driven oncology. Nucleai’s spatial-biology and artificial-intelligence capabilities could help Gilead identify biomarkers, improve patient selection and support its cancer-drug pipeline, although the financial impact remains uncertain. Does Gilead Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
• Positive Sentiment: BMO Capital reaffirmed its Buy rating, reinforcing the view that Gilead’s HIV franchise, oncology investments and pipeline can support further gains. BMO Capital Reaffirms Buy Rating on Gilead Sciences
• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast from a loss of $1.05 to a loss of $0.65 and increased its FY2027 estimate from $9.11 to $9.30. Several quarterly estimates for late 2026 and 2027 were also raised, suggesting improving expectations for future profitability.
• Neutral Sentiment: The recent rally extended to seven consecutive sessions, indicating strong momentum, but the subsequent consolidation may reflect profit-taking as the stock trades near its 52-week high. Gilead Rises for the Seventh Straight Session
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82, equivalent to $3.28 annually and a yield of roughly 2.3%. The payout supports income-oriented investors, though the reported negative payout ratio reflects currently distorted earnings.
• Negative Sentiment: Zacks lowered its FY2028 EPS forecast from $10.00 to $9.58 and cut estimates for Q1 and Q2 2028. Although several nearer-term estimates increased, the mixed revisions signal uncertainty around the longer-term earnings trajectory.
• Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares for approximately $415,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan and left him with substantial holdings, making it a limited bearish signal, but insider selling can weigh modestly on sentiment. Gilead Sciences CFO Sells 3,000 Shares

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider owned 118,234 shares in the company, valued at $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the transaction, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at $22,918,780.56. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 82,000 shares of company stock valued at $10,837,860. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $143.44 on Friday. The firm has a market capitalization of $177.86 billion, a PE ratio of -53.72 and a beta of 0.32. The business’s fifty day moving average price is $131.56 and its 200 day moving average price is $136.52. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.01 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Analyst Ratings Changes

GILD has been the subject of several analyst reports. Rothschild & Co Redburn lowered their target price on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Royal Bank Of Canada lifted their price objective on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research report on Wednesday, May 20th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Barclays reduced their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Twenty-four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.